STOCK TITAN

Morphic to Participate in RBC Capital Markets Global Healthcare Conference

Morphic Therapeutic (Nasdaq: MORF) will participate in the 2024 RBC Capital Markets Global Healthcare Conference where Dr. Marc Schegerin, COO and CFO, will engage in a fireside chat on May 15th.

(Neutral)
(Neutral)
Tags
conferences

Rhea-AI Summary

Morphic Therapeutic (Nasdaq: MORF) will participate in the 2024 RBC Capital Markets Global Healthcare Conference where Dr. Marc Schegerin, COO and CFO, will engage in a fireside chat on May 15th. The company is focused on developing oral integrin therapies for chronic diseases.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.
Argus Session date unavailable
-1.75% session move Open Argus
Details

News Market Reaction – MORF

The recorded move for MORF in the trading session of this news was -1.75%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Marc Schegerin, COO and CFO, will take part in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at 9:00 AM ET.

A live webcast of the panel discussion and fireside chat at the RBC Global Healthcare Conference will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Dr. Marc Schegerin participate in the RBC Capital Markets Global Healthcare Conference?

Dr. Marc Schegerin will participate in the conference on May 15th at 9:00 AM ET.

What is the focus of Morphic Therapeutic?

Morphic Therapeutic is developing a new generation of oral integrin therapies for serious chronic diseases.

Where can the live webcast of the panel discussion and fireside chat be viewed?

The live webcast will be available on the Investor section of Morphic's website at www.morphictx.com.

Will there be an archived replay available?

Yes, an archived replay will be available on the company's website following the conference.

Keep reading